User:Mr. Ibrahem/Dexmedetomidine

Mr. Ibrahem/Dexmedetomidine
Clinical data
Trade names	Precedex, Dexdor, Dexdomitor, Sileo, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Dexmedetomidine;
Pregnancy; category	AU: B1; ;
Routes of; administration	Intravenous infusion, transmucosal, intranasal
Drug class	α2-adrenergic agonist
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	94%
Metabolism	Near complete liver metabolism to inactive metabolites
Elimination half-life	2 hours
Excretion	Urinary
Identifiers
	IUPAC name (S)-4-[1-(2,3-Dimethylphenyl)ethyl]-3H-imidazole;
Chemical and physical data
Formula	C13H16N2
Molar mass	200.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc2cccc([C@H](C)c1c[nH]cn1)c2C;
	InChI InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1 ; Key:CUHVIMMYOGQXCV-NSHDSACASA-N ;
	(verify)

Dexmedetomidine, sold under the trade name Precedex among others, is a medication used for procedural sedation or sedation in the intensive care unit.^[1] It results in mild to moderate sedation without much effect on breathing.^[1] It is used by intravenous infusion.^[1] Onset of effects may take 25 minutes.^[2]

Common side effects include low blood pressure, nausea, dry mouth, and an abnormal heart rate.^[1] Other side effects may include agitation, high blood sugar, increased body temperature, and decreased breathing.^[3] It works by blocking the α₂-adrenergic receptors present in certain parts of the brain.^[4]

Dexmedetomidine was approved for medical use in the United States in 1999 and Europe in 2011.^[1]^[5] It is available as a generic medication.^[3] In the United Kingdom a 1 mg vial costs about £78 as of 2020.^[3] Veterinarians may use it for similar purposes in other animals.^[6]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Dexmedetomidine Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 22 July 2021.
^ Barash, Paul G.; Cullen, Bruce F.; Stoelting, Robert K.; Cahalan, Michael; Stock, M. Christine (1 January 2011). Clinical Anesthesia. Lippincott Williams & Wilkins. p. PT3627. ISBN 978-1-4511-2297-8. Archived from the original on 28 August 2021. Retrieved 22 July 2021.
^ ^a ^b ^c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1416. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ Cormack JR, Orme RM, Costello TG (2005). "The role of alpha2-agonists in neurosurgery". Journal of Clinical Neuroscience. 12 (4): 375–8. doi:10.1016/j.jocn.2004.06.008. PMID 15925765. S2CID 79899746.
^ "Dexdor". Archived from the original on 8 January 2021. Retrieved 22 July 2021.
^ "Dexdomitor for Animal Use". Drugs.com. Archived from the original on 25 May 2016. Retrieved 22 July 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Dexmedetomidine Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 22 July 2021.

[Bar2011-2] Barash, Paul G.; Cullen, Bruce F.; Stoelting, Robert K.; Cahalan, Michael; Stock, M. Christine (1 January 2011). Clinical Anesthesia. Lippincott Williams & Wilkins. p. PT3627. ISBN 978-1-4511-2297-8. Archived from the original on 28 August 2021. Retrieved 22 July 2021.

[BNF80-3] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1416. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[Cormack2005-4] Cormack JR, Orme RM, Costello TG (2005). "The role of alpha2-agonists in neurosurgery". Journal of Clinical Neuroscience. 12 (4): 375–8. doi:10.1016/j.jocn.2004.06.008. PMID 15925765. S2CID 79899746.

[5] "Dexdor". Archived from the original on 8 January 2021. Retrieved 22 July 2021.

[6] "Dexdomitor for Animal Use". Drugs.com. Archived from the original on 25 May 2016. Retrieved 22 July 2021.

[1]

[2]

[3]

[4]

[5]

[6]